Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejim.2020.05.011 http://scihub22266oqcxt.onion/10.1016/j.ejim.2020.05.011 32448770!7241995!32448770     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Intern+Med 2020 ; 76 (ä): 36-42 Nephropedia Template TP {{tp|p=32448770|t=2020. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy |pdf=|usr=}}{{32448770}} gab.com Text Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy JO: Eur J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32448770 #FOAvip BACKGROUND: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19. METHODS: In this open-label prospective study we describe clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab intravenously. All patients had elevated IL-6 plasma level (>40 pg/mL) and oxygen saturation <93% in ambient air. Clinical outcomes, oxygen support, laboratory data and adverse events were collected over a follow-up of 30 days. RESULTS: Forty-five patients (88%) were on high-flow oxygen supplementation, six of whom with invasive ventilation. From baseline to day 7 after tocilizumab we observed a dramatic drop of body temperature and CRP value with a significant increase in lymphocyte count (p<0.001). Over a median follow-up time of 34 days from tocilizumab, 34 patients (67%) showed an improvement in their clinical severity class; 31 were discharged; 17 (33%) showed a worsening of their clinical status, of these 14 died (27%). The mortality rate was significantly associated with mechanical ventilation at baseline (83.3% vs 20% of patients on non-invasive oxygen support; p=0.0001). The most frequent side effects were an increase of hepatic enzymes (29%), thrombocytopenia (14%), and serious bacterial and fungal infections (27%). CONCLUSION: Tocilizumab exerts a rapidly beneficial effect on fever and inflammatory markers, although no significant impact on the clinical outcome can be inferred by our results. Critically ill patients seem to have a high risk of serious infections with this drug. Twit Text FOAVip Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy ????Eur J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32448770 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32448770 #FOAvip English Wikipedia <ref>{{Cite pmid|32448770}}</ref> Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy #MMPMID32448770 Morena V; Milazzo L; Oreni L; Bestetti G; Fossali T; Bassoli C; Torre A; Cossu MV; Minari C; Ballone E; Perotti A; Mileto D; Niero F; Merli S; Foschi A; Vimercati S; Rizzardini G; Sollima S; Bradanini L; Galimberti L; Colombo R; Micheli V; Negri C; Ridolfo AL; Meroni L; Galli M; Antinori S; Corbellino M Eur J Intern Med 2020[Jun]; 76 (ä): 36-42 PMID32448770show ga BACKGROUND: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19. METHODS: In this open-label prospective study we describe clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab intravenously. All patients had elevated IL-6 plasma level (>40 pg/mL) and oxygen saturation <93% in ambient air. Clinical outcomes, oxygen support, laboratory data and adverse events were collected over a follow-up of 30 days. RESULTS: Forty-five patients (88%) were on high-flow oxygen supplementation, six of whom with invasive ventilation. From baseline to day 7 after tocilizumab we observed a dramatic drop of body temperature and CRP value with a significant increase in lymphocyte count (p<0.001). Over a median follow-up time of 34 days from tocilizumab, 34 patients (67%) showed an improvement in their clinical severity class; 31 were discharged; 17 (33%) showed a worsening of their clinical status, of these 14 died (27%). The mortality rate was significantly associated with mechanical ventilation at baseline (83.3% vs 20% of patients on non-invasive oxygen support; p=0.0001). The most frequent side effects were an increase of hepatic enzymes (29%), thrombocytopenia (14%), and serious bacterial and fungal infections (27%). CONCLUSION: Tocilizumab exerts a rapidly beneficial effect on fever and inflammatory markers, although no significant impact on the clinical outcome can be inferred by our results. Critically ill patients seem to have a high risk of serious infections with this drug. |*Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects[MESH] |*Coronavirus Infections/blood/epidemiology/physiopathology/therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/blood/diagnosis/drug therapy/epidemiology/etiology/physiopathology/therapy[MESH] |*Respiratory Insufficiency/etiology/therapy[MESH] |Antiviral Agents/adverse effects[MESH] |Betacoronavirus/drug effects/isolation & purification[MESH] |COVID-19[MESH] |Female[MESH] |Fever/diagnosis/drug therapy[MESH] |Humans[MESH] |Italy/epidemiology[MESH] |Lymphocyte Count/methods[MESH] |Male[MESH] |Middle Aged[MESH] |Outcome and Process Assessment, Health Care[MESH] |Receptors, Interleukin-6/*antagonists & inhibitors[MESH] |Respiration, Artificial/*methods[MESH] |Retrospective Studies[MESH]Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia(epmc).pdf DeepDyve Pubget Overpricing